Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MGTX Meiragtx Holdings Plc

Market Closed 08-14 16:00:00 EDT

13.52

+0.85

+6.71%

盘后13.52

+0.000.00%

19:34 EDT

High13.77	Low12.39	Vol809.17K
Open12.46	D1 Closing12.67	Amplitude10.89%
Mkt Cap1.30B	Tradable Cap753.58M	Total Shares96.04M
T/O10.87M	T/O Rate1.45%	Tradable Shares55.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MGTX","market":"US","secType":"STK","nameCN":"Meiragtx Holdings Plc","latestPrice":13.52,"timestamp":1786737600000,"preClose":12.67,"halted":0,"volume":809173,"hourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.52,"latestTime":"19:34 EDT","volume":14007,"amount":189375.24,"timestamp":1786750444561,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06708760852407258,"floatShares":55738000,"shares":96043000,"eps":-1.48811,"marketStatus":"Market Closed","change":0.85,"latestTime":"08-14 16:00:00 EDT","open":12.46,"high":13.77,"low":12.39,"amount":10866027.371707,"amplitude":0.108919,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.48811,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1528430400000,"exchange":"NASDAQ","adjPreClose":12.67,"preHourTrading":{"tag":"盘前","latestPrice":12.38,"preClose":12.67,"latestTime":"09:29 EDT","volume":741,"amount":9414.493179,"timestamp":1786714141586,"change":-0.29,"changeRate":-0.022889,"amplitude":0.179953},"postHourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.52,"latestTime":"19:34 EDT","volume":14007,"amount":189375.24,"timestamp":1786750444561,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.9621642728618998,"impliedVol":1.032,"impliedVolPercentile":0.6135},"requestUrl":"/m/hq/s/MGTX","defaultTab":"news","newsList":[{"id":"2659717188","title":"Profit Surge and New Leadership Might Change The Case For Investing In MeiraGTx Holdings (MGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659717188","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659717188?lang=en_us&edition=fundamental","pubTime":"2026-08-16 09:23","pubTimestamp":1786843407,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings plc reported past second-quarter 2026 results showing revenue rising to US$321.43 million from US$3.69 million a year earlier, with net income improving to US$160.72 million from a US$38.8 million loss, alongside key leadership hires and a US$12.96 million shelf registration for 1,000,000 ordinary shares tied to an employee share plan.\nBy pairing a shift to profitability with senior executives experienced in taking complex therapies through approval and commercialization,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgtx/meiragtx-holdings/news/profit-surge-and-new-leadership-might-change-the-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgtx/meiragtx-holdings/news/profit-surge-and-new-leadership-might-change-the-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MGTX","BK4139","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129647","title":"Emmaus Life Sciences Q2 Revenue Soars on Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129647","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129647?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:20","pubTimestamp":1786738826,"startTime":"0","endTime":"0","summary":"Emmaus Life Sciences Q2 revenue soars on licensing dealOverviewUS biopharmaceutical firm's Q2 revenue rose 124% yr/yr, driven by NIT license agreementCompany reduced operating expenses following sales","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETON","RANI","EMMA","BK4539","BK4139","MGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659312657","title":"Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2659312657","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659312657?lang=en_us&edition=fundamental","pubTime":"2026-08-15 03:29","pubTimestamp":1786735753,"startTime":"0","endTime":"0","summary":"Inflammation drug developer HCW Biologics' Q2 net loss widensOverviewUS biopharma firm's Q2 revenue rose yr/yr, driven by licensing agreement completionCompany posted higher Q2 net loss compared to pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","HCWB","VTGN","BK4139","BK4007","MGTX","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659284921","title":"MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659284921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659284921?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:02","pubTimestamp":1786723359,"startTime":"0","endTime":"0","summary":"MeiraGTx  is moving closer to becoming a commercial-stage company, with two potential first-in-class treatments approaching approval, RBC Capital Markets said Thursday in a report.For X-linked retinitis pigmentosa, a rare inherited eye disease that causes progressive vision loss, MeiraGTx expects to file its biologics license application with the US Food and Drug Administration in 2026 and launch the treatment in 2027, the report said.For xerostomia, or chronic dry mouth, the Phase 2 study has finished enrollment and is on track to report 12-month results in Q2 2027, the report said. MeiraGTx expects to file with the FDA in mid-2027, with a possible approval late that year and a US launch in early 2028, RBC said.The company ended Q2 with $145 million in cash and expects to have funding into H2 2028, the report said.RBC raised its price target on MeiraGTx stock to $27 from $26 and maintained its outperform speculative risk rating.Price: 13.03, Change: +0.36, Percent Change: +2.84","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146826","title":"RBC Adjusts PT on MeiraGTx to $27 From $26, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146826","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146826?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:39","pubTimestamp":1786707571,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings (MGTX) has an average rating of buy and mean price target of $29.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145152","title":"Bank of America Securities Remains a Buy on Meiragtx Holdings (MGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:15","pubTimestamp":1786706124,"startTime":"0","endTime":"0","summary":"In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Meiragtx Holdings, with a price target of $19...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-meiragtx-holdings-mgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-meiragtx-holdings-mgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0683600562.USD","BK4553","LU0320765646.SGD","LU2596442595.SGD","LU1035773651.USD","LU1880398554.USD","BK4534","IE0001KFT4U8.USD","KBWB","PGF","LU0098860793.USD","LU0070302665.USD","LU0310800965.SGD","LU0868494617.USD","XLF","UYG","LU0130517989.USD","LU0130103400.USD","LU0971096721.USD","FNCL","LU0787776722.HKD","MGTX","LU1804176565.USD","LU0256863811.USD","LU1280957306.USD","LU1989771016.USD","LU0980610538.SGD","IYF","LU1496350171.SGD","LU0648000940.SGD","LU1496350502.SGD","LU0052756011.USD","BK4588","IE00BLSP4452.SGD","LU0640476718.USD","LU0306807586.USD","BAC","LU1791807156.HKD","LU0130102774.USD","LU0321505868.SGD","LU0306806265.USD","FTXO","LU0314106906.USD","LU1366192091.USD","LU1883839398.USD","LU0203345920.USD","TFNS","LU0477156797.USD","VFH","IYG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659216654","title":"MeiraGTx Gains; Reports over $200 Mln in License Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659216654","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659216654?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:03","pubTimestamp":1786637026,"startTime":"0","endTime":"0","summary":"BUZZ-MeiraGTx gains; reports over $200 mln in license revenue** Shares of genetic medicine firm MeiraGTxMGTX.Orise 6% to $13.74** Company reports Q2 revenue of $321.43 million, including $204.6 million in license revenue. There was no license revenue a year earlier** License revenue relates to MeiraGTx's proprietary gene therapy delivery platform, which enables precise, small-volume brain infusions and has been licensed to Reogen Limited for the development of neurology-focused therapies, including Parkinson's disease** Including session's move, MGTX shares up 73% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659303168","title":"MeiraGTx Holdings PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659303168","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659303168?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:07","pubTimestamp":1786630064,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings SummaryMeiraGTx Holdings PLCMGTX.OQreported quarterly adjusted earnings of 86 cents per share for the quarter ended June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659574871","title":"Sector Update: Healthcare Stocks Advance Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2659574871","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659574871?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:13","pubTimestamp":1786626787,"startTime":"0","endTime":"0","summary":"Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF  up 0.3% and the iShares Biotechnology ETF  0.6% higher.MeiraGTx  shares were up more than 7% after the company reported that it swung to a Q2 net income as revenue surged during the period.Cullinan Therapeutics , Taiho Oncology and Taiho Pharmaceutical said a phase 3 clinical trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy as a first-line treatment for adults with previously untreated, locally advanced or metastatic non-small cell lung cancer met its primary endpoint of progression-free survival. Shares of Cullinan Therapeutics were up more than 7% premarket.Ascendis Pharma  stock was up more than 1% after the company posted higher Q2 non-IFRS earnings and revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4137","CGEM","BK4139","IBB","LU0889565916.HKD","LU0109394709.USD","LABU","LU0029874061.USD","MEDI","LU0128526141.USD","MGTX","BK4581","LU0320765992.SGD","XBI","BK4585","ASND","BK4588","XLV","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152820","title":"Shares of MeiraGTx Climb 7.1% Premarket After Q2 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152820?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:33","pubTimestamp":1786624396,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154238","title":"MeiraGTx Posts Corporate Deck Highlighting Late-Stage Gene Therapy Pipeline, Riboswitch Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154238","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154238?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:23","pubTimestamp":1786623836,"startTime":"0","endTime":"0","summary":"MeiraGTx posts corporate deck highlighting late-stage gene therapy pipeline, riboswitch platformMeiraGTx highlighted four late-stage gene therapy programs, led by AAV-AQP1 in pivotal Phase 2 for radia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL25jY8d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659460154","title":"MeiraGTx Q2 Revenue Jumps on Reogen License Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659460154","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659460154?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:22","pubTimestamp":1786623742,"startTime":"0","endTime":"0","summary":"MeiraGTx Q2 revenue jumps on Reogen license revenueOverviewUK-U.S. genetic medicines firm's Q2 revenue surgedCompany posted net income after a loss in the prior-year quarterMeiraGTx completed bota-vec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT","ABEO","TSHA","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659549061","title":"MeiraGTx Hldgs Q2 Sales $321.434M Beat $12.476M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659549061","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659549061?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:16","pubTimestamp":1786623388,"startTime":"0","endTime":"0","summary":"MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly sales of $321.434 million which beat the analyst consensus estimate of $12.476 million by 2.48K percent.  This is a 8.61K percent increase over sales of $3.691 million the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61171799/meiragtx-hldgs-q2-sales-321-434m-beat-12-476m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659545011","title":"Earnings Flash (MGTX) MeiraGTx Posts Q2 Net Income $1.71 a Share, vs. FactSet Est of $0.35 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659545011","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659545011?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:10","pubTimestamp":1786623046,"startTime":"0","endTime":"0","summary":"Earnings Flash (MGTX) MeiraGTx Posts Q2 Net Income $1.71 a Share, vs. FactSet Est of $0.35 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154383","title":"MeiraGTx Q2 FY26 Net Income Swings to USD 160.7 Million; Revenue Jumps to USD 321.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154383","media":"Reuters","labels":["shareholding","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154383?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:07","pubTimestamp":1786622864,"startTime":"0","endTime":"0","summary":"MeiraGTx Q2 FY26 net income swings to USD 160.7 million; revenue jumps to USD 321.4 millionMeiraGTx swung to net income of $160.7 million, or $1.76 per share, in Q2 2026 from a net loss.Revenue climbe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL19f1V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","MGTX","BK4112","LU2095319765.USD","BK4139","SG9999014039.USD","SG9999014021.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659514291","title":"MeiraGTx Q2 Income from Operations USD 244.425 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659514291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659514291?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXDFHNS6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315431","title":"MeiraGTx Q2 EPS USD 1.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315431?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXDFHNS6:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154963","title":"Corrected-MeiraGTx Q2 Revenue USD 321.4 Million VS. Ibes Estimate USD 12.5 Million (Corrects Amount)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154963?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXDFHNS6:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919355","title":"Graviton Bioscience Announces Clearance of Investigational New Drug (Ind) for Gv101 for the Treatment of Friedreich's Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658919355?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:30","pubTimestamp":1786458602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA3K7BB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658356919","title":"MeiraGTx - Enrollment for Phase 2 Gv101 Trial Expected to Begin in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2658356919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658356919?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:30","pubTimestamp":1786458602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA3K7BB9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.meiragtx.com","stockEarnings":[{"period":"1week","weight":0.0344},{"period":"1month","weight":0.0764},{"period":"3month","weight":0.4383},{"period":"6month","weight":0.8148},{"period":"1year","weight":0.623},{"period":"ytd","weight":0.7006}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.012037},{"month":2,"riseRate":0.5,"avgChangeRate":0.0333},{"month":3,"riseRate":0.25,"avgChangeRate":-0.052743},{"month":4,"riseRate":0.75,"avgChangeRate":-0.013966},{"month":5,"riseRate":0.625,"avgChangeRate":0.013491},{"month":6,"riseRate":0.5,"avgChangeRate":0.058638},{"month":7,"riseRate":0.555556,"avgChangeRate":0.008569},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.024141},{"month":9,"riseRate":0.75,"avgChangeRate":-0.003363},{"month":10,"riseRate":0.375,"avgChangeRate":0.087707},{"month":11,"riseRate":0.625,"avgChangeRate":0.051284},{"month":12,"riseRate":0.625,"avgChangeRate":0.053515}],"exchange":"NASDAQ","name":"Meiragtx Holdings Plc","nameEN":"Meiragtx Holdings Plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Meiragtx Holdings Plc(MGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Meiragtx Holdings Plc,MGTX,Meiragtx Holdings Plc股票,Meiragtx Holdings Plc股票老虎,Meiragtx Holdings Plc股票老虎国际,Meiragtx Holdings Plc行情,Meiragtx Holdings Plc股票行情,Meiragtx Holdings Plc股价,Meiragtx Holdings Plc股市,Meiragtx Holdings Plc股票价格,Meiragtx Holdings Plc股票交易,Meiragtx Holdings Plc股票购买,Meiragtx Holdings Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Meiragtx Holdings Plc(MGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction